Boehringer Snags Austrian Biopharma Co. In $245M Deal
Germany-based Boehringer Ingelheim is taking over an Austrian biotechnology company that focuses on developing cancer treating immunotherapeutics in a $245 million deal, the companies announced Thursday....To view the full article, register now.
Already a subscriber? Click here to view full article